Scribd
Upload
8 views14 pages

Cancer Risk Assessment of PAHs

The document discusses the assessment of cancer health risks associated with exposure to multi-component polycyclic aromatic hydrocarbons (PAHs) using relative potency factors (RPF) related to benzo[a]pyrene (B[a]P). It outlines the calculation of B[a]P equivalent concentrations and the incremental lifetime cancer risk (ILCR) for different exposure routes, including ingestion, inhalation, and dermal contact. The document also provides cancer slope factors for B[a]P and indicates that an ILCR value between 10^-6 and 10^-4 suggests potential risk.

Uploaded by

wflhafsiufi
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
8 views14 pages

Cancer Risk Assessment of PAHs

The document discusses the assessment of cancer health risks associated with exposure to multi-component polycyclic aromatic hydrocarbons (PAHs) using relative potency factors (RPF) related to benzo[a]pyrene (B[a]P). It outlines the calculation of B[a]P equivalent concentrations and the incremental lifetime cancer risk (ILCR) for different exposure routes, including ingestion, inhalation, and dermal contact. The document also provides cancer slope factors for B[a]P and indicates that an ILCR value between 10^-6 and 10^-4 suggests potential risk.

Uploaded by

wflhafsiufi
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

Cancer Health Risk

Assessment
Lecture 5
⚫For estimating the health risk posed by exposure to
multi-component PAH, relative potency factors,
(RPF) relative to B[a]P based on a RPF scheme
developed by (EPA,2003 and EPA,2010).
⚫RPF values are mandatory to connect various PAHs
to benzo[a]pyrene since the dose-response data for
BaP are well studied and allows for the combining of
adverse effects accompanied by concurrent exposure
to several individual PAHs. ‫اﻟﻣﺗزاﻣن‬
⚫The following table lists several RPF values used in
these risk assessment calculation.
⚫ In a first step, a B[a]P equivalent concentration
(B[a]Peq) is calculated by the multiplication of the
individual PAH concentration by its RPF.
⚫The carcinogenic potency of all considered PAHs can
then be estimated as the sum of each individual
B[a]Peq.
PAHs with final relative potency factors
based on tumor bioassay data
⚫The following equation was used to convert the PAH
concentrations into its BaP “equivalent”
concentration.
⚫The sum of the individual equivalent concentrations
was then used as the exposure concentration in the
lifetime average daily dose calculations.
⚫=∑[𝑃𝐴𝐻]𝑖 × 𝑅𝑃𝐹𝑖
For cancer risk assessment
determination

⚫Incremental Lifetime Cancer Risk (ILCR) of PAHs


attached to suspended particulates is calculated for
ingestion and dermal routes and PAHs attached to
gaseous phase is calculated for inhalation route.
⚫Assuming that there are only three major routes of
contact; ingestion, inhalation, and dermal contact
with dust particles; the total carcinogenic risk could
Toxic Equivalent
be evaluated by using TEQ values as previously
mentioned; intake rates and particle emission could
be estimated by those developed for soil particles
(Pongpiachan, 2015).
LADDinh is the lifetime average daily dose associated with the
inhalation (mg/ kg/d), Cg = the gas phase atmospheric
concentration of each individual PAH (ng/m3), ET = the exposure
time (h/d), EF = the exposure frequency (d/y), InhR = inhalation
rate (m3/d), IngR = ingestion rate (mg/d), ED = exposure duration
(years), BW = body weight (kg), ATcar = average timing for
carcinogenic health effects (days) and cf = conversion factor.
LADDing is the lifetime average daily dose associated
with the ingestion (mg/ kg/d), Cp = the particulate
phase concentration of each individual PAH (µg/g),
IngR = ingestion rate (mg/d),
LADDder is the lifetime average daily dose
associated with the dermal exposure (mg/
kg/d), ABS = dermal adsorption fraction
(dimensionless), SA = skin surface area
exposed (cm2), AFd = particle-to-skin
adherence factor (mg/cm2/event)
ILTCRi = incremental lifetime cancer risk
for an exposure route (i), LADDi = lifetime
average daily dose for an exposure route (i)
and CSFi = cancer slope factor for an
exposure route (i).
Total incremental lifetime cancer
risk
⚫CSF Ingestion: Carcinogenic slope factor for ingestion
of B[a] P (7.3 mg kg–1 day–1) –1
⚫ CSF Dermal: Carcinogenic slope factor for dermal of
B[a] P (25 mg kg–1 day–1) –1
⚫CSF Inhalation: Carcinogenic slope factor for
inhalation of B[a] P (3.85 mg kg–1 day–1) –1
⚫For the most regulatory programs, a value of ILCR
between 10-6to 10-4signifies potential risk

You might also like